Researchers Compare Hypofractionated High-dose IMRT Schedules in Prostate Cancer

Share this content:
A recent study examined the efficacy of differing high-dose IMRT schedules on prostate cancer treatment.
A recent study examined the efficacy of differing high-dose IMRT schedules on prostate cancer treatment.

A hypofractionated high-dose intensity-modulated radiotherapy (IMRT) schedule consisting of 60 Gy over 20 fractions showed improved efficacy compared with 57 Gy over 19 fractions and was non-inferior to 74 Gy over 37 fractions with a similar low level of acute and delayed normal tissue damage, a study presented at the 2016 Genitourinary Cancers Symposium has shown.1

For the phase 3 CHHiP trial, researchers sought to explore the dose response relationship for two 3 Gy hypofractionated IMRT schedules for the treatment of T1b-3a N0 localized prostate cancer.

Researchers enrolled 3216 men with localized disease and randomly assigned them 1:1:1 to receive hypofractionated schedules of 60 Gy in 20 fractions or 57 Gy in 19 fractions, or conventional RT consisting of 74 Gy in 37 fractions. Of those, 15% had low-risk disease, 73% had intermediate-risk, and 12% had high-risk disease.

Results showed that at a median follow-up of 5.2 years, the 5-year progression-free survival rate was 88.3% (95% CI, 86.0 - 90.2) with 74 Gy, 90.6% (95% CI, 88.5 - 92.3) with 60 Gy, and 85.9% (95% CI, 83.4 - 88.0) with 57 Gy. Hazard ratios were 0.83 (90% CI, 0.68 - 1.03) for 60 Gy compared with 70 Gy, and 1.20 (90% CI, 0.99 - 1.45) for 57 Gy compared with 74 Gy.

Researchers observed significantly more progression events with the 57 Gy schedule compared with the 60 Gy schedule (HR, 1.44; 90% CI, 1.18 - 1.75; P = .003).

In regard to safety, there was no significant difference in gastrointestinal or genitourinary toxicity between the hypofractionated RT schedules. At 2 years, there was no statistically significant difference between the rates of genitourinary (P = .34) or gastrointestinal (P = .10) toxicities between the 3 arms.


  1. Dearnaley DP, Syndikus I, Mossop H, et al. Comparison of hypofractionated high-dose intensity-modulated radiotherapy schedules for prostate cancer: results from the phase III randomized CHHiP trial (CRUK/06/016). J Clin Oncol. 2016; 34 (suppl 2S; abstr 2).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs